Leerink Partnrs Has Negative Outlook of Penumbra Q1 Earnings

Penumbra, Inc. (NYSE:PEN) – Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Penumbra in a research report issued to clients and investors on Tuesday, February 18th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of $0.69 for the quarter, down from their previous estimate of $0.83. The consensus estimate for Penumbra’s current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for Penumbra’s Q2 2025 earnings at $0.83 EPS, FY2025 earnings at $3.61 EPS and FY2026 earnings at $5.54 EPS.

PEN has been the topic of several other research reports. Citigroup lifted their price target on Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Morgan Stanley lifted their price target on Penumbra from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday. StockNews.com raised Penumbra from a “hold” rating to a “buy” rating in a research report on Thursday. Robert W. Baird lifted their price target on Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Wells Fargo & Company lifted their price target on Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $292.64.

Penumbra Price Performance

Shares of NYSE PEN opened at $302.82 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. Penumbra has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The firm has a market capitalization of $11.66 billion, a PE ratio of 890.64, a price-to-earnings-growth ratio of 2.23 and a beta of 0.53. The stock’s 50-day simple moving average is $258.16 and its 200-day simple moving average is $227.04.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The business had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million.

Insider Activity at Penumbra

In other Penumbra news, CEO Adam Elsesser sold 15,000 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the sale, the chief executive officer now directly owns 837,582 shares in the company, valued at approximately $203,498,922.72. The trade was a 1.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Lambert Shiu sold 1,798 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $242.56, for a total value of $436,122.88. Following the sale, the chief accounting officer now owns 20,682 shares in the company, valued at approximately $5,016,625.92. The trade was a 8.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,219 shares of company stock worth $4,426,439 over the last three months. 5.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Penumbra

A number of institutional investors have recently bought and sold shares of PEN. True Wealth Design LLC purchased a new stake in shares of Penumbra in the third quarter valued at $26,000. UMB Bank n.a. lifted its position in shares of Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after acquiring an additional 70 shares in the last quarter. Hurley Capital LLC purchased a new stake in shares of Penumbra in the fourth quarter valued at $56,000. Huntington National Bank lifted its position in shares of Penumbra by 138.7% in the fourth quarter. Huntington National Bank now owns 265 shares of the company’s stock valued at $63,000 after acquiring an additional 154 shares in the last quarter. Finally, Mather Group LLC. lifted its position in shares of Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after acquiring an additional 208 shares in the last quarter. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.